Development and validation of a TRUS-based prostate cancer prediction model with PSAD stratification in a two-center Western Chinese cohort: a retrospective cohort study with cost-effectiveness analysis

Prostate-specific antigen screening has a low positive predictive value in low-incidence populations, leading to unnecessary biopsies. In this study, we developed and validated a prostate cancer prediction model incorporating transrectal ultrasound features and prostate-specific antigen density stratification and evaluated its cost-effectiveness. This dual-center retrospective study included 767 men with prostate-specific antigen levels of ≥4 ng ml-1 (training cohort, n = 558; validation cohort, n = 209). Prostate-specific antigen density was stratified into five categories. A logistic regression model was developed and validated. The cost-effectiveness of four screening strategies was evaluated. Five independent predictors were identified: age, prostate-specific antigen density stratification, extraprostatic extension, solid hypoechoic lesions, and unclear boundary. The model showed good discrimination (0.915 and 0.943 in the training and validation cohorts, respectively) and calibration (Hosmer-Lemeshow P = 0.57). The high-threshold strategy (≥0.5) avoided 47.0% of biopsies, and had the lowest total cost. In the biopsy cohort, the cost per cancer detected was the lowest in men with prostate-specific antigen density ≥0.15 ng ml-2 (83 295 Chinese Yuan). This model can reduce unnecessary biopsies in men with elevated prostate-specific antigen levels identified from opportunistic testing, but it is not suitable for population-wide screening given its unfavorable cost-effectiveness. It provides incremental value in resource-limited settings rather than serves as a practice-changing alternative to contemporary magnetic resonance imaging (MRI)-based pathways.

Authors

Institutions

Publication Details

Journal
Asian Journal of Andrology
Published
2026-11-17
DOI
https://doi.org/10.4103/aja202656
Primary Topic
Prostate Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Development and validation of a TRUS-based prostate cancer prediction model with PSAD stratification in a two-center Western Chinese cohort: a retrospective cohort study with cost-effectiveness analysis

Xin Ai, Xue Li, Yu Liang, Yu-Min Yang et al.
1 links
Asian Journal of Andrology
Prostate Cancer Diagnosis and Treatment
article

Development and validation of a TRUS-based prostate cancer prediction model with PSAD stratification in a two-center Western Chinese cohort: a retrospective cohort study with cost-effectiveness analysis

Xin Ai, Xue Li, Yu Liang, Yu-Min Yang, Mao-Hua Lyu, Jun Luo, Jing Zhang, Yuan-Qiang Li, Yi-Qiong Zhang, Fei Li
article en

Abstract

Prostate-specific antigen screening has a low positive predictive value in low-incidence populations, leading to unnecessary biopsies. In this study, we developed and validated a prostate cancer prediction model incorporating transrectal ultrasound features and prostate-specific antigen density stratification and evaluated its cost-effectiveness. This dual-center retrospective study included 767 men with prostate-specific antigen levels of ≥4 ng ml-1 (training cohort, n = 558; validation cohort, n = 209). Prostate-specific antigen density was stratified into five categories. A logistic regression model was developed and validated. The cost-effectiveness of four screening strategies was evaluated. Five independent predictors were identified: age, prostate-specific antigen density stratification, extraprostatic extension, solid hypoechoic lesions, and unclear boundary. The model showed good discrimination (0.915 and 0.943 in the training and validation cohorts, respectively) and calibration (Hosmer-Lemeshow P = 0.57). The high-threshold strategy (≥0.5) avoided 47.0% of biopsies, and had the lowest total cost. In the biopsy cohort, the cost per cancer detected was the lowest in men with prostate-specific antigen density ≥0.15 ng ml-2 (83 295 Chinese Yuan). This model can reduce unnecessary biopsies in men with elevated prostate-specific antigen levels identified from opportunistic testing, but it is not suitable for population-wide screening given its unfavorable cost-effectiveness. It provides incremental value in resource-limited settings rather than serves as a practice-changing alternative to contemporary magnetic resonance imaging (MRI)-based pathways.

Asian Journal of Andrology
University of Electronic Science and Technology of China (CN), Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital (CN)
Good health and well-being
Prostate Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon